INCY stock forecast
Our latest prediction for Incyte Corp.'s stock price was made on the July 7, 2020 when the stock price was at 108.65$.
In the short term (2weeks), INCY's stock price should underperform the market by -1.04%. During that period the price should oscillate between -6.07% and +4.34%.
In the medium term (3months), INCY's stock price should underperform the market by -3.90%. During that period the price should oscillate between -18.52% and +12.07%.Get email alerts
Create a solid portfolio with INCY
About Incyte Corp.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
At the moment the company generates 2229M USD in revenues.
On its last earning announcement, the company reported a loss of -1.75$ per share.
The book value per share is 8.15$
Three months stock forecastJuly 7, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|